A Commentary on the VITAL Study: Does Vitamin D (receptor Activation) Protect Against Nephropathy in Type 2 Diabetes?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Effect of Vitamin D and Tacrolimus Combination Therapy on IgA Nephropathy.
Yuan D, Fang Z, Sun F, Chang J, Teng J, Lin S Med Sci Monit. 2017; 23:3170-3177.
PMID: 28659572 PMC: 5501071. DOI: 10.12659/msm.905073.
Sun Y, Jiang C, Cheng K, Zhang W, Leung G, Lam T PLoS One. 2015; 10(8):e0135380.
PMID: 26258947 PMC: 4530892. DOI: 10.1371/journal.pone.0135380.
References
1.
Deb D, Sun T, Wong K, Zhang Z, Ning G, Zhang Y
. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010; 77(11):1000-9.
DOI: 10.1038/ki.2010.22.
View
2.
de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T
. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376(9752):1543-51.
DOI: 10.1016/S0140-6736(10)61032-X.
View
3.
Alborzi P, Patel N, Peterson C, Bills J, Bekele D, Bunaye Z
. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008; 52(2):249-55.
DOI: 10.1161/HYPERTENSIONAHA.108.113159.
View
4.
Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N
. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009; 54(4):647-52.
DOI: 10.1053/j.ajkd.2009.04.036.
View
5.
Zhang Z, Sun L, Wang Y, Ning G, Minto A, Kong J
. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2007; 73(2):163-71.
DOI: 10.1038/sj.ki.5002572.
View